Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic.

Autor: Akimova AA; Research Institute of Clinical and Experimental Lymphology-Branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (RICEL-Branch of IC&G SB RAS), Novosibirsk, Russia. anya-zemtsova@mail.ru., Banshchikova NE; Federal State Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia., Sizikov AE; Federal State Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia., Mullagaliev AA; Research Institute of Clinical and Experimental Lymphology-Branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (RICEL-Branch of IC&G SB RAS), Novosibirsk, Russia., Letyagina EA; Research Institute of Clinical and Experimental Lymphology-Branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (RICEL-Branch of IC&G SB RAS), Novosibirsk, Russia., Ilina NA; Federal State Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia., Kurochkina YD; Research Institute of Clinical and Experimental Lymphology-Branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (RICEL-Branch of IC&G SB RAS), Novosibirsk, Russia., Ubshaeva YB; Research Institute of Clinical and Experimental Lymphology-Branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (RICEL-Branch of IC&G SB RAS), Novosibirsk, Russia., Omelchenko VO; Research Institute of Clinical and Experimental Lymphology-Branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (RICEL-Branch of IC&G SB RAS), Novosibirsk, Russia., Chumasova OA; Federal State Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia., Shkaruba NS; Federal State Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia., Korolev MA; Research Institute of Clinical and Experimental Lymphology-Branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (RICEL-Branch of IC&G SB RAS), Novosibirsk, Russia.
Jazyk: angličtina
Zdroj: Doklady. Biochemistry and biophysics [Dokl Biochem Biophys] 2024 Oct; Vol. 518 (1), pp. 291-299. Date of Electronic Publication: 2024 Jul 01.
DOI: 10.1134/S1607672924701060
Abstrakt: The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases (IRDs). This is primarily due to the negative impact of a number of basic disease-modifying antirheumatic drugs (DMARDs) and genetically engineered biological drugs (biological DMARDs, or biologics) on the course and outcomes of a new coronavirus infection. A number of studies have shown that anti-B-cell therapy (rituximab) gave a statistically significant increase in the risk of severe COVID-19 and an increase in mortality. At the same time, the analysis of real clinical practice data dictated the need to establish a number of restrictions on the use of certain classes of biologics and to search for alternative therapy programs to maintain control over disease activity.
Purpose of the Study: The purpose of the study was to evaluate the efficacy and safety of the drug Artlegia® (olokizumab), solution for subcutaneous injection, 160 mg/ml-0.4 ml, manufactured by R-Pharm JSC, Russia) for the treatment of patients with rheumatoid arthritis in real clinical practice after switching with rituximab during the COVID-19 pandemic.
Materials and Methods: The study included 14 patients with a confirmed diagnosis of rheumatoid arthritis (RA), who were previously on rituximab therapy at a dose of 1000-500 mg twice with an interval of 2 weeks, who received at least one course of therapy with this drug. As RA worsened, patients were switched to olokizumab against the background of standard DMARDs. On weeks 0, 4, 8, and 12 after the switch, the severity of pain was assessed on the VAS scale, the number of tender and swollen joints (TJC28 and SJC28), the level of acute-phase inflammation markers, the DAS28 (disease activity score), ESR, CRP, CDAI (clinical activity index), and the functional state index HAQ (Health Assessment Questionnaire) were determined, as well as the safety profile of therapy was assessed.
Results: Data analysis was performed using median values (Me) were used for data analysis. A significant decrease in TJC28 was detected after 8 and 12 weeks of treatment with olokizumab (Artlegia®) (Me baseline = 10, Me 8 weeks = 4, Me 12 weeks = 4, p < 0.05) and a decrease in TSC28 was detected after 4, 8, and 12 weeks of treatment (Me baseline = 9, Me 4 weeks = 3.5, Me 8 weeks = 2.5, Me 12 weeks = 2.0, p < 0.05). Laboratory markers of inflammation showed a decrease in CRP and ESR levels after 4 weeks of treatment (CRP: Me4 weeks = 21, Me4 weeks = 1, p < 0.05, ESR: Mesno = 31, Me4 weeks = 7, p < 0.05). Positive dynamics persisted on 8 and 12 weeks (CRP: Me 8 weeks = 1, Me 12 weeks = 0; ESR: Me 8 weeks = 4, Me 12 weeks = 5). The level of CRP by week 4 became within the normal range, regardless of the initial values. All activity indices improved from week 4 in each evaluation period compared to baseline: DAS28-ESR: Me baseline = 5.52, Me 4 weeks = 3.59, Me 8 weeks = 3.33, Me 12 weeks = 3.22, p < 0.05; DAS28CRP: Me baseline = 5.39, Me 4 weeks = 3.71, Me 8 weeks = 3.35, Me 12 weeks = 3.45, p < 0.05; CDAI: Me baseline = 28.5, Me 4 weeks = 18.0, Me 8 weeks = 16.5, Me 12 weeks = 16.0, p < 0.05. All patients showed a reduction in pain (VAS scale) by week 8. The functional status of patients, according to the HAQ index, showed a significant decrease only by week 12 of the study: Me baseline = 1.62, Me 12 weeks = 1.31, p < 0.05.
Conclusions: The study found that switching from rituximab to olokizumab was effective and safe during the COVID-19 pandemic.
(© 2024. Pleiades Publishing, Ltd.)
Databáze: MEDLINE
Externí odkaz: